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Abstract 
Background: While treatment of localised anal cancer (AC) is well established, very little 
evidence is available to inform the management of advanced tumours and the prognosis of 
these patients remains poor. We have analysed treatment pathways and outcomes of a single 
institution series of advanced AC patients in order to provide insight into the management of 
this rare condition.      
Material and methods: Inclusion criteria included epidermoid histology, inoperable locally 
recurrent or metastatic disease and availability of full medical records. The primary objective 
was overall survival (OS). Prognostic factors were analysed in univariate models. 
Results: Sixty-four patients (1997-2014) were included, 16 (25.0%) with inoperable locally 
advanced and 48 (75.0%) with metastatic tumours. Fifty-one (79.7%) received ≥1 line of 
chemotherapy and, of these, 37% underwent multimodality treatment. A combination of a 
platinum agent plus a fluoropyrimidine was the most common first-line regimen (74.5%) with 
an objective response rate (ORR) of 34.4% (95% CI: 18.6-53.2). Paclitaxel-based 
chemotherapy was used in 15 patients as either front-line or salvage treatment and the overall 
ORR was 53.3% (95% CI: 26.6-78.7). Median progression-free survival (PFS) after first- and 
second-line chemotherapy was 5.8 (IQR: 2.8-7.6) and 3.2 months (IQR: 2.5-7.1), respectively. 
5-year OS in the overall population was 15% (95% CI: 7.0-25.0). Age ≤65 years and liver 
metastases were predictive of better PFS (HR 0.39, 95% CI: 0.16-0.97, p=0.04) and worse OS 
(HR 2.25, 95% CI: 1.25-4.03, p=0.01), respectively.  
Conclusion: A platinum agent plus a fluoropyrimidine and paclitaxel-based chemotherapy are 
active regimens for advanced AC. Clinical trials are needed to standardise treatment pathways, 
investigate the potential of novel therapeutics and improve the poor prognosis of this rare 
condition.   
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Implications for practice 
Due to the lack of randomised trials, the optimal management of advanced anal cancer is 
uncertain. Despite the retrospective analysis and the relatively small sample size, this is the 
second largest study ever conducted in this setting and, as such, it has the potential to serve as 
a valuable source of information for everyday clinical practice. Based on our findings, 
chemotherapy with a platinum agent plus a fluoropyrimidine or paclitaxel-containing regimens 
are reasonable treatment options for patients with inoperable locally recurrent or metastatic 
anal carcinoma.  
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Introduction 
Approximately 27,000 individuals are estimated to have been diagnosed with anal cancer in 
2008 worldwide [1]. Although this tumour accounts for less than 1% of all new cancer 
diagnoses, incidence rates have progressively increased over the last few decades and more 
than doubled in some countries including UK and US [2]. This trend is likely to reflect an 
expansion of behavioural risk factors and predisposing medical conditions such as unsafe 
sexual practiceshuman immunodeficiency virus (HIV) infection/acquired immunodeficiency 
syndrome (AIDS) (especially after implementation of highly active antiretroviral therapy) and 
a prior history of vulvar/vaginal or cervical malignancy [3-9]. Epidermoid carcinomas account 
for the vast majority of anal tumours and an association with human papillomavirus (HPV) 
infection (especially HPV16 and HPV18) has been consistently reported in ~90% of cases [10-
12]. 
 
Usually anal cancer presents as a localised or locally-advanced tumour and in this setting 
chemoradiotherapy is an established treatment allowing sphincter preservation [13-15]. 
However, approximately 32% and 12% of patients experience isolated loco-regional 
recurrence and distant metastases, respectively [16]. While in the former group salvage surgery 
in the form of abdominoperineal resection (APR) is still a treatment with a potential for cure 
[17], palliative chemotherapy is the standard approach for inoperable or metastatic disease [10]. 
According to the Surveillance, Epidemiology, and End Results Program (SEER) statistics, only 
30.7% of patients with stage IV tumours are alive at 5 years [18], this figure confirming that 
long term survival in this patient population is an unmet need. 
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Like other rare cancers, randomised clinical trials are lacking and the only available evidence 
to inform the management of this condition comes from a limited number of small, single-
centre, retrospective studies where single-agent or combination chemotherapy regimens have 
been used in heterogeneous patient populations [19-33]. This uncertainty is reflected by the 
lack of strong recommendations from most international guidelines [34, 35]. Although doublet 
chemotherapy with cisplatin plus infusional fluorouracil is generally considered as the most 
reasonable first line treatment choice in fit patients, other cytotoxics including carboplatin, 
taxanes, doxorubicin and irinotecan or targeted therapies such as the anti-EGFR monoclonal 
antibody cetuximab are also viewed as potentially active agents. More importantly, 
participation in clinical trials is strongly encouraged.  
 
In this context, auditing and sharing institutional experiences with the international scientific 
community has the potential to either consolidate or challenge current practice and possibly 
convert anecdotal data into more robust, consensus-creating information to enhance the lack of 
high-quality, prospective evidence. Therefore, we have analysed treatment patterns and overall 
outcome of advanced anal cancer patients who were treated at our institution over a time period 
of approximately 17 years.  
 
Material and methods 
All patients who were seen in consultation at the Royal Marsden NHS Foundation Trust from 
1997 to 2014 following a diagnosis of anal cancer were reviewed. This study included only 
those patients who had histological confirmation of epidermoid anal carcinoma (i.e., 
squamocellular, basaloid or cloacogenic histotype), advanced disease (i.e., inoperable locally 
recurrent or metastatic tumours) and for whom full medical records were available. 
Demographics, clinico-pathological characteristics at baseline, treatments received before and 
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after the diagnosis of advanced disease and overall outcome data were retrospectively collected 
for each patient using the institutional electronic patient record system and entered into a 
database. 
 
The primary objective of the study was overall survival (OS). This was defined as time from 
date of diagnosis of advanced disease to date of death from any cause. Alive patients were 
censored at date of last follow-up. Secondary objectives included objective tumour response 
rate (defined as complete or partial response as per RECIST criteria version 1.1) and 
progression-free survival (PFS) (defined as time from start of treatment to date of progression 
or death from any cause) for first- and second-line chemotherapy. For the analysis of PFS, 
patients with no events were censored to date of subsequent line of chemotherapy. Both OS 
and PFS were analysed using the Kaplan-Meier method. In exploratory analyses, all outcome 
measures were also assessed by type of chemotherapy regimen. 
 
The prognostic value of selected factors including gender, age, tumour grading, time to 
development of advanced disease, number of metastatic sites, presence of liver metastases and 
response to first-line chemotherapy was tested in a univariate model. Cox regression was used 
to calculate hazard ratios and 95% confidence intervals. A p value <0.05 was considered 
statistically significant and no multiplicity adjustment was performed.  
 
The study was approved by the Research & Development Department at the Royal Marsden 
NHS Foundation Trust. Given that this was a retrospective analysis of clinical data, consent 
from patients included in the study was not required. 
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Results  
Sixty-four patients met the eligibility criteria and were included in the study. Demographics, 
clinico-pathological characteristics and previous treatments for non-advanced disease are 
reported in Table 1. There was a predominance of females (60.9%) and median age was 59.2 
years [interquartile range (IQR): 52.1 - 66.4]. The majority of patients (n=49, 76.6%) presented 
with localised or locally advanced disease while only 15 (23.4%) had distant metastases at 
diagnosis. Prior radiotherapy to the primary tumour was given to 53 patients (82.8%, in most 
cases with a curative intent) and 47 of these received concurrent chemotherapy with the most 
common radiosensitising regime being a combination of either 5-fluorouracil or capecitabine 
and mitomicin C. Eleven patients (17.2%) underwent prior salvage surgery including APR 
(n=10) and lung metastasectomy (n=1).   
 
Median time from the histological evidence of anal carcinoma to the diagnosis of advanced 
disease was 9.1 months [interquartile range (IQR): 4.1 – 20.9]. Distant metastases were present 
in 48 patients (75.0%) (extra-pelvic lymphadenopathy and liver metastases accounting for the 
majority of cases) while only 16 (25.0%) had inoperable locally advanced tumours. Only 51 
patients (79.7%) were treated with systemic chemotherapy (median number of chemotherapy 
lines: 1, range 0-5). Of the 13 patients who did not receive chemotherapy 5 were lost to follow-
up, 5 had poor performance status, 2 died before treatment and 1 was treated with only 
bisphosphonates and radiotherapy. 
 
Type of chemotherapy used in the study population is reported in Table 2. A fluoropyrimidine-
containing combination regimen was prescribed as first line treatment in 94.1% of patients 
(n=48) (fluoropyrimidine was actually replaced by raltitrexed to minimise the risk of 
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cardiovascular toxicity in a patient who experienced chest pain during previous capecitabine-
based chemoradiotherapy). In the vast majority of cases (n=38) 5-fluorouracil or capecitabine 
was given in combination with either cisplatin or carboplatin while in only 7 patients in 
combination with mitomicin C plus or minus cisplatin (2 of these had previously received 
mitomicin C with pelvic radiotherapy). Overall, median duration of first line treatment was 3.2 
months (IQR: 2.0 – 4.7) and an objective response was observed in 13/44 assessable patients 
(29.5%). Thirty-two patients who were treated with a fluoropyrimidine plus either cisplatin or 
carboplatin were assessable for response to treatment and among these the objective response 
rate was 34.4% (95% CI: 18.6 – 53.2). Following first line chemotherapy, 16 patients 
underwent multidisciplinary intervention including (chemo)radiotherapy to the primary tumour 
(n=5), APR/pelvic exenteration (n=6), inguinal node dissection (n=2), hepatectomy (n=1), and 
radiofrequency ablation (n=2, 1 liver and 1 lung). Median PFS was 5.8 months for both all 
study patients (IQR: 2.8 – 7.6) and those treated with a fluoropyrimidine plus either cisplatin 
or carboplatin (IQR: 2.9 – 7.6) (Figure 1). 
 
Second line systemic treatment was administered in 21 patients (32.8%). In most cases this 
consisted of a platinum agent plus or minus a fluoropyrimidine (n=9, including 7 patients who 
were re-challenged with the same class of agents used in the first line setting, 42.9%) or a 
paclitaxel-based regimen (n=8, 38.1%). Overall, median duration of second line treatment was 
2.6 months (IQR: 2.1 – 5.1) and an objective response was observed in 6 out of 18 assessable 
patients (33.3%). Following second line chemotherapy, 2 patients underwent multidisciplinary 
intervention including APR (n=1) and lung metastasectomy plus radiofrequency ablation to 
lung (n=1). Median PFS was 3.2 months (IQR: 2.5 – 7.1) (Figure 1). Subsequent lines of 
chemotherapy including investigational drugs within the context of clinical trials were 
administered in 12 patients (18.8%).  
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A total of 15 patients (excluding re-challenges) were treated with a paclitaxel-based 
chemotherapy (i.e., 12 with single agent paclitaxel and 3 with carboplatin plus paclitaxel) at 
some point during the course of their disease (2 in first line, 8 in second line and 5 in subsequent 
lines) and the overall response rate was 53.3% (95% CI: 26.6 – 78.7). Similarly, an objective 
response was observed in 4 out of 6 patients (all treated in the first line setting) who received 
a combination with a fluoropyrimidine plus mitomycin C. Irinotecan plus cetuximab was used 
as second line treatment in one patient who was subsequently lost to follow-up and as third line 
treatment in one patient with a KRAS exon 2 wild-type tumour who had disease progression as 
best response.  
 
Patients were followed-up for a median of 71.9 months (IQR 53.5 – 96.0). Median OS was 
14.1 months (IQR: 8.0 – 41.4) in the overall study population and 15.4 months (IQR: 10.0 – 
45.2) in the group of patients who received at least one line of systemic chemotherapy. Median 
OS from second line chemotherapy was 14.9 months (IQR: 9.4 – 37.4). The 5-year OS rate in 
the overall population was 15.0% (95% CI: 7.0-25.0) (Figure 2). When survival estimates were 
calculated from the date of initial diagnosis, median OS was 2.7 years (95% CI: 1.8 - 3.2) and 
5-year OS was 27% (95% CI: 16-39). Among the prognostic factors considered in the 
univariate analysis, age <65 years was found to be associated with a better PFS (HR 0.39; 95% 
CI: 0.16 – 0.97, p=0.04) while presence of liver metastases indicated a worse OS (HR 2.25; 
95% CI: 1.25 – 4.03, p=0.01) (Table 3). 
  
Discussion 
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In this retrospective study we have analysed treatment pathways and outcome of a consecutive 
series of patients who were managed for advanced anal cancer at a UK tertiary cancer centre 
over a period of approximately two decades.  
 
So far, the decision-making process for advanced anal cancer patients has been based on sub-
optimal quality evidence, this largely consisting of anecdotal case reports, case-series, phase I 
studies or small, single-arm phase II studies [19-33]. The relatively low incidence of this 
condition, the common pattern of clinical presentation at diagnosis and the high success rate of 
definitive chemoradiotherapy for early stage tumours have historically hampered the 
development of randomised clinical trials. Therefore no consensus has been reached and the 
optimal management of patients with advanced anal cancer is still a matter of controversy. 
 
Despite the relatively small sample size, this is the second largest study ever published on this 
topic and it has therefore the potential to serve as a valuable source of information for clinicians 
and patients who face uncertainty in the optimal management of this condition. The baseline 
characteristics of our study population were either consistent with those reported in similar 
studies or largely expected based on the established clinico-epidemiological features and 
natural history of anal cancer [32, 34, 35]. Females were predominant over males, the median 
age was relatively young and approximately 8% of patients had a known history of HIV 
infection. Although information on the HPV status was not available in our study, it is 
legitimate to assume that the vast majority of patients had HPV-positive tumours. Expectedly, 
in most cases previous chemoradiotherapy plus or minus subsequent salvage APR was 
administered with a curative intent for the management of early stage disease.    
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In keeping with common practice in most international centres and the recommendation from 
ESMO and NCCN guidelines [34, 35], a combination regime with a platinum agent plus a 
fluoropyrimidine was used for the majority of chemotherapy-naïve patients with an overall 
objective response rate of 34.4% and a median PFS of 5.8 months. Although these figures 
confirm the activity of this doublet chemotherapy, they appear somehow lower than those 
previously reported for the combination of cisplatin plus infusional fluorouracil in previous 
series [22, 32]. However, substantial heterogeneity across studies especially in terms of number 
and clinico-pathological characteristics of assessable patients and the retrospective evaluation 
of response to treatment may account for the observed difference.  
 
Over the last few years, evidence has emerged suggesting that paclitaxel-based chemotherapy 
may also be a valuable treatment option for patients with advanced anal cancer. The use of 
single agent paclitaxel in this setting was first described by Alcindor et al and Abbas et al who 
reported promising rates of clinical benefit in small case series of chemotherapy-naïve or 
previously treated patients [26, 29]. Subsequently, partial response rates ranging from 33% to 
69% were observed in untreated patients with the combination of carboplatin plus paclitaxel 
[31, 32]. Also, in a small phase I study, intra-arterial administration of nab-paclitaxel led to 
partial response in 58% of cases [24]. Our study provides further support to the contention that 
paclitaxel, either as a single agent or in combination with a platinum agent, should be 
considered as one of the most effective, currently available, options in the therapeutic 
armamentarium for advanced anal cancer. Indeed, we observed an overall response rate of 
53.3% that is particularly interesting especially if we consider that in most cases our patients 
received this agent as monotherapy in the refractory setting.  
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Additional therapeutic approaches including triplet chemotherapy and anti-EGFR monoclonal 
antibodies have been reported as potentially effective in this setting [23, 25, 27, 28, 30, 33]. In 
our study such treatments were used in only 4 and 2 patients, respectively, this largely 
precluding any meaningful analysis or comparison with other series. Assessing the activity of 
mitomycin in our series is also challenging due to the same reasons. However, the proportion 
of objective responses observed in the group of patients treated with a combination of 
mitomycin and a fluoropyrimidine (4 out of 6) seem to suggest that, in addition to the 
established role in the early stage setting, a mitomycin-based treatment may also be considered 
as a valid therapeutic option for the management of patients with advanced tumours.  
 
Although our analysis focused on the efficacy of treatments, safety is an important 
consideration when making decision for patients with advanced anal cancer. We did not report 
toxicity data and this is certainly a limitation of our study. However, retrospective collection 
of patient reported adverse events is subject to a number of biases and may not provide a 
reliable estimate of the overall burden of treatment-related morbidities. Moreover, safety 
profile of the chemotherapy regimens that were used in our patient population is well known 
these being routinely prescribed in several tumour types.   
 
We confirmed that a multidisciplinary approach might play an important role in the 
management of advanced anal cancer. In our series 37% of patients who received at least one 
line of chemotherapy were also deemed suitable candidates for loco-regional procedures 
including surgical resection of the primary tumour or metastases, chemoradiotherapy to the 
primary tumour and radiofrequency ablation of metastatic lesions. Multidisciplinary 
management of advanced anal cancer has been considered by Eng et al as an effective strategy 
with the potential to improve the outcome of selected anal cancer patients [32]. Although 
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evaluation of the true effect of a multimodality treatment approach in this setting is hampered 
by inherent selection biases, we share the opinion that consideration should be given whenever 
feasible to adopt any additional therapeutic strategy that can possibly consolidate the effect of 
previous systemic treatments.     
 
In our series age and liver metastases were found to be prognostic factors. However, we 
recommend caution when interpreting these findings. Our univariate analysis of predictive 
factors for PFS and OS should be considered as exploratory given the small sample size and 
the significant patient heterogeneity especially in terms of baseline characteristics and 
treatments. Larger series are certainly needed to identify and validate clinico-pathological 
factors that could be used for treatment selection in routine practice or patient stratification in 
clinical trials.  
    
Long-term outcome of our patient population was in line with previously reported data [31, 
35]. Median overall survival was 14 months and only 13% of patients were alive 5 years after 
the diagnosis of advanced disease. These disappointing figures suggest that long-term disease 
control is still an unmet need in this setting and there is significant scope for improvement. In 
this regard, there has recently been increased awareness within the scientific community of the 
need to standardise treatment pathways and investigate novel therapeutics. The International 
Rare Cancer Initiative (IRCI) group has recently promoted the development of the first 
INTERnational Advanced Anal Cancer Trial (InterAACT), a global, randomised phase II study 
that is comparing efficacy and safety of cisplatin plus fluorouracil versus carboplatin plus 
paclitaxel for the first line treatment of patients with inoperable locally recurrent or metastatic 
anal carcinoma (NCT02051868) [37]. Moreover, studies aiming to provide a molecular 
characterisation of anal cancer have been increasingly reported and revealed genetic alterations 
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and aberrant signaling pathways which can be possibly investigated as valuable therapeutic 
targets [38, 39]. Finally, preliminary evidence has been reported suggesting that 
immunotherapy may be an effective strategy for the management of this disease [40, 41].    
 
Conclusion 
The purpose of this study was to provide insight into the management of advanced anal cancer. 
Although the study was neither designed nor powered to determine any superiority of one 
chemotherapy regimen versus the other, our results confirm that a combination of a platinum 
agent plus a fluoropyrimidine is a reasonable first line treatment choice in these patients and 
provide further support to the decision to use a paclitaxel-based regimen in the comparator arm 
of the InterAACT trial. A number of limitations and biases are inherent to small single 
institution studies that are solely based on retrospective patient data collection. Hence such 
studies are regarded as suboptimal by international guidelines that rank levels of evidence. 
Nevertheless, in the absence of better quality studies, they still provide important evidence to 
guide the management of patients with this rare condition, establish an international consensus 
and collaborative database and inform the design of future clinical trials. 
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OBJECTIVES 
 
 
 
 
 
 
 
 
Conducting international 
multicentre clinical trials 
is paramount to optimise 
and standardise 
treatment for rare 
cancers.  
 
No randomised clinical 
trials have ever been 
conducted in the setting 
of advanced anal cancer.     
 
 
 
 
There is currently no 
consensus on the optimal 
management of 
advanced anal cancer. 
 
Systemic chemotherapy 
in the form of 
combination regimens is 
the most common 
treatment approach. 
 
Variability across 
international institutions 
exists and a universally 
accepted treatment 
pathway cannot be 
identified.   
 
 
 
 
 Significant uncertainty 
regarding treatment of 
advanced anal cancer 
remains and decisions in 
everyday clinical 
practice are largely 
empirical.  
 
No significant progress 
has been made over the 
last few decades in the 
management of 
advanced anal cancer 
and the prognosis of 
patients with advanced 
anal cancer remains 
poor.  
 
To consider the lack of 
high-quality evidence for 
the management of 
advanced anal cancer 
 
 
To obtain useful 
information on treatment 
pathways and outcomes 
for patients with 
advanced anal cancer 
treated in a large    
tertiary cancer centre 
 
 
To consider the 
importance of 
conducting prospective 
randomised clinical trials 
in advanced anal cancer 
and other rare tumour 
types   
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Figures 
Figure 1. Progression-free survival after first-line (A) and second-line (B) chemotherapy in the 
chemotherapy-treated population 
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Figure 2. Overall survival from advanced disease in the overall population 
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Table 1. Patient characteristics  
 
 N % 
Gender 
     Female 39 60.9 
     Male 25 39.1 
Age 
     Median (range) 59.2 (35.4 - 85.2) 
HIV infection 
     No known history 59 92.2 
     Yes  5 7.8 
Histology 
     Squamous cell carcinoma 58 90.6 
     Squamous cell carcinoma – Basaloid 5 7.8 
     Squamous cell carcinoma - Epidermoid 1 1.6 
Tumour grade 
     Moderately differentiated 30 46.9 
     Poorly differentiated 25 39.1 
     Unknown 9 14.0 
Stage (TNM) at diagnosis 
     I-II-III 49 76.6 
     IV 15 23.4 
Prior radiotherapy to the primary tumour 
     No 11 17.2 
     Yes 53 82.8 
          (Curative) (44) (83.0) 
          (Palliative) (7) (13.2) 
          (After resection of primary tumour) (2) (3.8)  
Prior radiosensitising chemotherapy 
     No 6 11.3 
     Yes 47 88.7 
          (fluoropyrimidine + MMC) (36) (76.6) 
          (fluoropyrimidine alone) (4) (8.5)  
          (fluoropyrimidine + cisplatin) (5) (10.6) 
          (Other) (2) (4.3) 
Prior salvage APR   
     No 54 84.4 
     Yes 10 15.6 
Time to advanced disease – months 
     Median (range) 9.3 (0 – 130.5) 
          ≤ 12 months 38 59.4 
          > 12 months 26 40.6 
Extent of disease before 1st line chemotherapy 
     Locally advanced 16 25.0 
     Metastatic 48 75.0 
Number of sites of disease 
     1 43 67.2 
     >2 21 32.8 
Sites of disease 
     Extrapelvic nodes 22 34.4 
     Liver 21 32.8 
     Pelvis 16 25.0 
     Lung 11 17.2 
     Bone 8 12.5 
     Other 7 10.9 
 
Abbreviations: MMC: mitomycin C; APR: abdominoperineal resection.   
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Table 2. Chemotherapy regimens used in the first and second line setting 
 
 
 
N 
 
% 
 
FIRST LINE CHEMOTHERAPY (N=51) 
 
Cisplatin/Carboplatin + Fluoropyrimidine (or Raltitrexed)  38 74.5 
          (Carboplatin + Capecitabine) (22) (43.1) 
          (Cisplatin + Capecitabine) (8) (15.7) 
          (Cisplatin + 5-fluorouracil) (6) (11.8) 
          (Carboplatin + 5-fluorouracil) (1) (2.0) 
          (Carboplatin + Raltitrexed) (1) (2.0) 
 
MMC + Fluoropyrimidine (+/- Platinum agent) 7 13.7 
          (MMC + Capecitabine) (3) (5.9) 
          (MMC + 5-Fluorouracil + Cisplatin) (3) (5.9) 
          (MMC + 5-Fluorouracil) (1) (2.0) 
 
 Other   6 11.8 
 
 
SECOND LINE CHEMOTHERAPY (N=21) 
 
Cisplatin/Carboplatin +/- Fluoropyrimidine  9 42.9 
          (Carboplatin + Capecitabine) (6) (28.6) 
          (Cisplatin + Capecitabine) (1) (4.8) 
          (Cisplatin + 5-fluorouracil) (1) (4.8) 
          (Cisplatin) (1) (4.8) 
 
Paclitaxel +/- Carboplatin   8 38.1 
          (Paclitaxel) (7) (33.3) 
          (Carboplatin + Paclitaxel) (1) (4.8) 
 
Other 4 23.8 
 
 
Abbreviations: MMC: mitomycin C.  
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Table 3. Univariate analysis of prognostic factors for progression-free survival and overall survival  
 
Variable 
 
PFS 
 
 
OS 
 
 
HR (95% CI) 
 
p value HR (95% CI) p value 
Gender 
Female - - - - 
Male 1.66 (0.81-3.41) 0.17 1.41 (0.80-2.48) 0.23 
 
Age 
<65 - - - - 
≥65 0.39 (0.16-0.97) 0.04 1.05 (0.57-1.93) 0.87 
 
Tumour grade 
Moderate - - - - 
Poor 1.09 (0.52-2.29) 0.81 0.85 (0.47-1.51) 0.57  
 
Liver metastases 
No - - - - 
Yes 1.07 (0.49-2.33) 0.87 2.25 (1.25-4.03) 0.01  
 
N of sites of disease 
0-1 - - - - 
1+ 0.97 (0.42-2.24) 0.94 1.66 (0.89-3.10) 0.11  
 
Time to advanced disease 
< 12m - - - - 
≥ 12m 0.49 (0.23-1.04) 0.06 1.24 (0.71-2.16) 0.46  
 
Response to 1st line 
chemotherapy 
No - - - - 
Yes 0.62 (0.28-1.39) 0.25 0.61 (0.29-1.28) 0.19  
 
 
 
Abbreviations: PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence intervals.  
 
 
